Michael A. Platt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Michael A. Platt has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Liwen Song
Department of Chemistry, University of Oxford Chemistry Research Laboratory Mansfield Road Oxford OX1 3TA U.K
2 shared publications - Stuart J. Conway
University of California, Los Angeles
2 shared publications Alistair M. Boyd
Department of Chemistry, University of Oxford Chemistry Research Laboratory Mansfield Road Oxford OX1 3TA U.K
1 shared publication- Alistair M. Boyd
University of Oxford
1 shared publication - Annabel Eardley-Brunt
Department of Chemistry, University of Oxford, Chemistry Research Laboratory, 12 Mansfield Rd, Oxford OX1 3TA, UK
1 shared publication Antoine L. D. Wallabrègue
Department of Chemistry, University of Oxford Chemistry Research Laboratory Mansfield Road Oxford OX1 3TA U.K
1 shared publication
Latest Publications
- Open Access
- 17 November 2025
- Published by Wiley in Chemistry – A European Journal
- Vol. 31 (72) , e03011
High‐Affinity Peptide‐Drug Conjugate Ligands for the TRIM24 PHD and Bromodomain
TRIM24 is an epigenetic transcriptional coregulator that “reads” KMe 3 and KAc histone modifications via its tandem plant homeodomain (PHD) and bromodomain (BRD), respectively. The PHD and BRD are potential therapeutic targets due to the roles of TRIM24 in breast cancer progression. However, there are currently no small‐molecule ligands for the PHD, and existing TRIM24 BRD inhibitors lack selectivity over the main off‐target, BRPF1. Here, we report the development of the first bivalent tool molecules capable of simultaneously engaging both the TRIM24 PHD and BRD. Key to this strategy was the identification of effective KMe 3 bioisosteres that enhance H3 peptide binding to the TRIM24 PHD. The most promising of these was incorporated into a nine amino acid H3‐mimicking peptide, and linked to a TRIM24 BRD ligand. The resulting peptide‐drug conjugates (PDCs) bind to TRIM24 with picomolar affinity and a slow dissociation rate ( k off ), which is driven by an in cis bivalent binding mode. Although the PDCs showed limited effects on breast cancer cell proliferation in vitro, this work underscores their potential as tools for studying previously unliganded reader domains and consequently advancing our understanding of multivalent epigenetic regulation in disease.
- 17 November 2025
- Published by Wiley in Chemistry – A European Journal
- Vol. 31 (72) , e03011
Open AccessHigh‐Affinity Peptide‐Drug Conjugate Ligands for the TRIM24 PHD and Bromodomain
TRIM24 is an epigenetic transcriptional coregulator that “reads” KMe 3 and KAc histone modifications via its tandem plant homeodomain (PHD) and bromodomain (BRD), respectively. The PHD and BRD are potential therapeutic targets due to the roles of TRIM24 in breast cancer progression. However, there are currently no small‐molecule ligands for the PHD, and existing TRIM24 BRD inhibitors lack selectivity over the main off‐target, BRPF1. Here, we report the development of the first bivalent tool molecules capable of simultaneously engaging both the TRIM24 PHD and BRD. Key to this strategy was the identification of effective KMe 3 bioisosteres that enhance H3 peptide binding to the TRIM24 PHD. The most promising of these was incorporated into a nine amino acid H3‐mimicking peptide, and linked to a TRIM24 BRD ligand. The resulting peptide‐drug conjugates (PDCs) bind to TRIM24 with picomolar affinity and a slow dissociation rate ( k off ), which is driven by an in cis bivalent binding mode. Although the PDCs showed limited effects on breast cancer cell proliferation in vitro, this work underscores their potential as tools for studying previously unliganded reader domains and consequently advancing our understanding of multivalent epigenetic regulation in disease.
- Open Access
- 1 July 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Development and Evaluation of High Affinity Peptide-Drug Conjugate Ligands for the TRIM24 PHD and Bromodomain
TRIM24 is an epigenetic transcriptional coregulator that ‘reads’ KMe3 and KAc histone modifications via its tandem plant homeodomain (PHD) and bromodomain (BRD), respectively. The PHD and BRD are potential therapeutic targets due to the roles of TRIM24 in breast cancer progression. However, there are currently no small molecule ligands for the PHD, and existing TRIM24 BRD inhibitors lack selectivity over the main off-target, BRPF1. Here, we report the development of the first bivalent tool molecules capable of simultaneously engaging both the TRIM24 PHD and BRD. Key to this strategy was the identification of effective KMe3 bioisosteres that enhance H3 peptide binding to the TRIM24 PHD. The most promising of these was incorporated into a nine amino acid H3-mimicking peptide, and linked to a TRIM24 BRD ligand. The resulting peptide-drug conjugates (PDCs) bind to TRIM24 with picomolar affinity and a slow dissociation rate (koff), which is driven by an in cis bivalent binding mode. Although the PDCs showed limited effects on breast cancer cell proliferation in vitro, this work underscores their potential as tools for studying previously unliganded reader domains and consequently advancing our understanding of multivalent epigenetic regulation in disease.
- 1 July 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessDevelopment and Evaluation of High Affinity Peptide-Drug Conjugate Ligands for the TRIM24 PHD and Bromodomain
TRIM24 is an epigenetic transcriptional coregulator that ‘reads’ KMe3 and KAc histone modifications via its tandem plant homeodomain (PHD) and bromodomain (BRD), respectively. The PHD and BRD are potential therapeutic targets due to the roles of TRIM24 in breast cancer progression. However, there are currently no small molecule ligands for the PHD, and existing TRIM24 BRD inhibitors lack selectivity over the main off-target, BRPF1. Here, we report the development of the first bivalent tool molecules capable of simultaneously engaging both the TRIM24 PHD and BRD. Key to this strategy was the identification of effective KMe3 bioisosteres that enhance H3 peptide binding to the TRIM24 PHD. The most promising of these was incorporated into a nine amino acid H3-mimicking peptide, and linked to a TRIM24 BRD ligand. The resulting peptide-drug conjugates (PDCs) bind to TRIM24 with picomolar affinity and a slow dissociation rate (koff), which is driven by an in cis bivalent binding mode. Although the PDCs showed limited effects on breast cancer cell proliferation in vitro, this work underscores their potential as tools for studying previously unliganded reader domains and consequently advancing our understanding of multivalent epigenetic regulation in disease.
- Open Access
- 12 May 2025
- Published by Royal Society of Chemistry (RSC) in The Analyst
- Vol. 150 (12) , 2620-2631
Advancing atmospheric solids analysis probe mass spectrometry applications: a multifaceted approach to optimising clinical data set generation
We assess the impact of various experimental factors on ASAP-MS spectra, and make a series of recommendations to optimise the reliability and reproducibility of such measurements in clinical settings.
- 12 May 2025
- Published by Royal Society of Chemistry (RSC) in The Analyst
- Vol. 150 (12) , 2620-2631
Open AccessAdvancing atmospheric solids analysis probe mass spectrometry applications: a multifaceted approach to optimising clinical data set generation
We assess the impact of various experimental factors on ASAP-MS spectra, and make a series of recommendations to optimise the reliability and reproducibility of such measurements in clinical settings.